Skip to content
DataLookout
Menu

NCT07626515

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Primary and study completion moved earlier from May 14, 2027 to Apr 8, 2027
    • Site details revised
  2. Notable Eligibility criteria expanded, about 9 words
  3. Minor Primary completion date: Apr 30, 2027 to May 14, 2027
    • Study completion date: May 30, 2027 to May 14, 2027
    v3
  4. Notable Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 26, 2026 to Jul 2, 2026
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence and Severity of Adverse Events
Timeframe: Baseline to Safety Follow-Up (27 weeks)
Number of Participants with Abnormal Clinical Laboratory Parameters as a Shift from Baseline to Maximum Postbaseline Severity Grade
Timeframe: Baseline to Safety Follow-Up (27 weeks)
Change from Baseline in Pulse Rate
Timeframe: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)
Change from Baseline in Respiratory Rate
Timeframe: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)
Change from Baseline in Systolic Blood Pressure
Timeframe: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)
Change from Baseline in Diastolic Blood Pressure
Timeframe: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)
Change from Baseline in Body Temperature
Timeframe: At prespecified time points from Baseline to Safety Follow-Up (27 weeks)

Secondary (7)

Plasma Concentration of Enicepatide
Maximum Plasma Concentration Observed (Cmax) of Enicepatide
Time to Cmax (Tmax) of Enicepatide
Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUClast) of Enicepatide
Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Enicepatide
Show 2 moreShow less
Absolute Change From Baseline in Body Weight
Percent Change From Baseline in Body Weight

Arms and interventions

Enicepatide Dose 1Experimental
Enicepatide Dose 2Experimental
PlaceboPlacebo comparator

Combination products: Enicepatide, Placebo

Sites

1 site in 1 country

  • Peking University First HospitalBeijing, China